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Abstract
Background: Breast cancers lacking the estrogen receptor (ER) can be distinguished from other breast cancers on the basis
of poor prognosis, high grade, distinctive histopathology and unique molecular signatures. These features further
distinguish estrogen receptor negative (ER2) tumor subtypes, but targeted therapy is currently limited to tumors over-
expressing the ErbB2 receptor.
Methodology/Principal Findings: To uncover the pathways against which future therapies could be developed we
undertook a meta-analysis of gene expression from five large microarray datasets relative to ER status. A measure of
association with ER status was calculated for every Affymetrix HG-U133A probe set and the pathways that distinguished
ER2 tumors were defined by testing for enrichment of biologically defined gene sets using Gene Set Enrichment Analysis
(GSEA). As expected, the expression of the direct transcriptional targets of the ER was muted in ER2 tumors, but the
expression of genes indirectly regulated by estrogen was enhanced. We also observed enrichment of independent MYC-
and E2F-driven transcriptional programs. We used a cell model of estrogen and MYC action to define the interaction
between estrogen and MYC transcriptional activity in breast cancer. We found that the basal subgroup of ER2 breast cancer
showed a strong MYC transcriptional response that reproduced the indirect estrogen response seen in estrogen receptor
positive (ER+) breast cancer cells.
Conclusions/Significance: Increased transcriptional activity of MYC is a characteristic of basal breast cancers where it
mimics a large part of an estrogen response in the absence of the ER, suggesting a mechanism by which these cancers
achieve estrogen-independence and providing a potential therapeutic target for this poor prognosis sub group of breast
cancer.
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Introduction
Breast cancers are routinely classified into estrogen receptor
positive (ER+) and estrogen receptor negative (ER2). These
tumor types have distinct molecular phenotypes [1]. ER+ cancers
may respond to anti-estrogens such as tamoxifen [2], although a
significant proportion demonstrate resistance to endocrine thera-
py. ER2 tumors fail to respond to endocrine therapy and have a
poor prognosis when compared to ER+ tumors [2]. The genetic
pathways utilized by ER2 tumors to proliferate in the absence of a
mitogenic estrogen (E2) signal are poorly understood. Elucidation
of these pathways is required for the development of improved
therapies for ER2 patients. Currently the only targeted therapy
for ER2 tumors is a monoclonal antibody against the ErbB2
receptor (ERBB2), Herceptin, which is indicated in ER2/
Progesterone Receptor (PGR)2/ERBB2+ patients. The genetic
mechanisms responsible for proliferation in ER2 tumors could
also allow ER+ tumors to exhibit intrinsic or acquired endocrine
resistance and so develop a functional ER2 tumor status.
Several studies have defined sets of genes with differential
expression levels between ER+ and ER2 tumor types [3–5].
Others have defined the smallest gene set that discriminates
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ERBB2+ and molecular basal (predominantly high grade/ER2/
PGR2/ERBB22/basal cytokeratin +) [1], with a view to
producing better prognostic markers. These gene sets show a
small overlap restricted to only the most differentially expressed
genes [4], preventing the definition of common pathways.
Integration of data from multiple studies by a meta-analysis
provides the statistical power necessary to define common genetic
pathways and to provide new biological insight into the cause of
phenotypic diversity in breast cancer. A meta-analysis minimizes
individual study biases, and identifies genes with small but
consistent expression changes that might not have passed
significance thresholds in individual studies.
We have conducted a meta-analysis of five independent breast
cancer cohorts with the objective of producing a comprehensive
measure of differential expression between ER+ and ER2 tumors
for every probe set on the Affymetrix HG-U133A chip. We
present the first study with sufficient numbers of tumors to
separate the confounding effects of grade and ER status. The
genetic pathways and mechanisms active in ER+ and ER2
tumors were elucidated using two different approaches to
functional annotation analysis of the meta-analysis results – testing
for over-representation of functional categories using Database for
Annotation, Visualization, and Integrated Discovery (DAVID) [6],
and for enrichment of public and in-house gene lists using gene set
enrichment analysis (GSEA) [7]. We related the functional
annotation and GSEA results to the subtypes of breast cancer in
three independent validation datasets. We show that enhanced
transcriptional activity of MYC within the basal subgroup of ER2
breast cancer mimics aspects of the transcriptional response to
estrogen seen in ER+ cancers. This finding provides a mechanism
that allows ER2 tumors to overcome the absence of ER and
establishes MYC and its transcriptional targets as candidates for
the development of novel therapies for the basal subgroup of
breast cancer.
Materials and Methods
Data Collection
Five datasets of primary breast tumors profiled on Affymetrix
HG-U133A microarrays [8–11] were used in this meta-analysis.
Data from [11] were split into two datasets, those from Uppsala
University Hospital (Sotiriou.Uppsala), and the others from the
John Radcliffe Hospital who did not receive adjuvant systemic
therapy (Sotiriou.JRH.Untreated). HG-U133B data from [9] were
excluded. Each dataset was normalized and log2 probe-set
intensities calculated using the Robust Multichip Averaging
(RMA) algorithm [12]. Subset datasets of Elston-Ellis Grade 3
tumors containing a total of 82 ER2 and 101 ER+ patients were
then created for use in the meta-analysis (refer Text S1 for patient
characteristics).
Three independent RMA-normalized breast cancer datasets
[13–15] were used for validation of the meta-analysis and
molecular subtype analysis (Text S1). The Richardson dataset
[13] of Grade 3 tumors and normal samples, designated tumors as
‘‘Basal’’, ‘‘BRCA1’’ (positive for BRCA1 mutations) or ‘‘Non BLC’’
(non-basal-like cancer) by immunohistochemistry (IHC). For the
Wang dataset [14] we used the relative transcript levels of ER
(probe set ID 205225_at), PGR (208305_at), ERBB2 (216836_s_at)
and KRT5 (201820_at) to identify basal samples. ER status was not
available for the Pawitan cohort [15]. These samples had however
been classified into the molecular subtypes of Perou et al. [16] by
Pawitan et al. [15], (refer the GSE1456 series deposited in the
Gene Expression Omnibus http://www.ncbi.nlm.nih.gov/geo),
and these classifications were retained in our study.
Meta-analysis
Meta-analysis [17] was carried out using functions implemented
in the GeneMeta package [18]. The change in a gene’s expression
level between ER+ and ER2 tumors in each individual study was
expressed as an effect size, which is a unit-free standardized mean
difference between conditions measuring the magnitude of a
covariate effect corrected for sample size bias. The effect size of
each HG-U133A probe set in each dataset was entered into a
random effects model which takes into account intra- and inter-
study variability to produce a Z score as described in Text S1. A
negative Z score indicates a probe set with higher intensity in ER2
tumors. The statistical significance of differential expression was
calculated by converting the Z scores to P-values which were then
adjusted for multiple testing using the Benjamini-Yekutieli (BY)
correction [19]. The transformed weighted average ratio (tWAR),
which provides an indication of the fold-change between ER+ and
ER2 tumors, was calculated as described in Text S1.
Functional annotation analysis
Sets of selected genes were tested for over-representation of
functional annotation categories, including gene ontology (GO)
and protein domain categories, using tools within DAVID version
2007 [6] (refer Text S1 for category details). The BY correction for
multiple testing was applied to the EASE scores, and the
significance threshold set at adjusted P#0.05. Cell cycle maps
were obtained from the GenMapp database [20], and genes within
the map colored using tWARs and adjusted P-values from the
meta-analysis.
Statistical analysis of validation datasets
Complete linkage hierarchical clustering was performed on data
scaled so that all probe-sets shared the same mean and variance,
using the euclidean distance metric in the stats package in R [21].
The difference in mean probe set intensities between sets of genes
in basal and non-basal ER2 samples, or between basal and
normal samples in the validation data sets was assessed using a
two-sided paired t-test. For individual genes of interest, the
difference in mean intensity was assessed using a two-sided Welch
two-sample t-test.
Analysis of MYC and E2 datasets for differential
expression
Transcript profiling data from the studies of Bild et al. [22],
Carroll et al. [23] and the in-house study of Musgrove et al. [24]
(GSE11791 series deposited in the Gene Expression Omnibus)
were RMA-normalized and analyzed for differential expression
using LIMMA [25]. No intensity or fold-change filters were used,
and the significance threshold for differential expression was set at
BY adjusted P,0.05.
Gene Set Enrichment Analysis (GSEA)
GSEA [7] was used to determine if the members of a given gene
set were generally associated with ‘‘ER2’’ tumor status, and was
therefore performed on all 22,283 probe sets on the HG-U133A
chip ranked by meta-analysis Z score from most negative to most
positive. The gene list was collapsed to unique gene symbols using
the default capabilities. The maximum gene set size was fixed at
1500 genes, and the minimum size fixed at 15 genes. 1000 random
sample permutations were carried out, and the significance
threshold set at FDR,0.05. If a gene set had a positive
MYC and E2F
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expression in ER2 tumors than in ER+ tumors, and the set was
termed ‘‘enriched’’ in ER2 tumors. If a set had a negative
enrichment score it was termed ‘‘depleted’’ in ER2 tumors. An
initial screening of gene sets enriched in ER2 tumors was carried
out using the Molecular Signature Database (MolSigDB) c1.v2,
c2.v2 and c3.v2 gene sets current as of March 2007 (data not
shown). On consideration of the results, other published gene sets
relating to the action of E2, MYC and E2Fs were curated and
added to the MolSigDB lists in a second GSEA screen.
Results
Meta-analysis of ER+ vs. ER2 tumors
A meta-analysis approach [17] was used to obtain overall
measures for gene expression in ER+ and ER2 tumors from 5
datasets. All datasets consisted of fresh-frozen primary breast
cancers profiled on the Affymetrix HG-U133A platform with
information on ER status and grade. The meta-analysis was
restricted to Grade 3 tumors (82 ER2, 101 ER+), to overcome the
association between grade and ER status, and was verified in three
independent datasets. Details of the 8 data sets used are provided
in Text S1. Measures for ER status association were obtained for
all 22,283 HG-U133A probe sets and are presented in the
searchable Table S1, of which 2141 (9.6%) were differentially
expressed between ER+ and ER2 tumors with adjusted P,0.01.
This set is referred to as the ER status-associated (ERA) genes.
To explore whether the results from Grade 3 tumors may be
extended to tumors of other grades, we performed a Principal
Components Analysis of Grade 2 tumors using the ERA genes
(Figure S1). The ERA genes separated the ER+ and ER2 Grade 2
tumors indicating that many of the genes differentially expressed in
Grade 3 tumors are also differentially expressed in the Grade 2
tumors.
The ERA genes were used to cluster the tumors from three
independent validation datasets, visualized in the form of
heatmaps (Figure 1). In each heatmap, two main gene clusters
were produced. The top cluster in each heatmap corresponds to
ERA genes that are more highly expressed (red in color) in ER+
tumors and expressed at lower level (blue in color) in ER2 tumors.
The bottom cluster corresponds to ERA genes that show the
converse pattern of expression. The ER status of the tumors is
indicated along the top of the heatmap and demonstrates that the
ERA gene set can correctly delineate ER+ and ER2 tumors in the
independent data sets, so validating their intended capacity.
Importantly, within the ER2 tumors in all three datasets, the
ERA genes clearly delineated the basal (Richardson set, Figure 1A),
predicted basal (Wang set, Figure 1B) or molecular basal (Pawitan
set, Figure 1C) subtypes from the ER2/ERBB2+ subtypes. The
expression of ERBB2 is indicated along the top of each heatmap,
as is the expression of Keratin 5 (KRT5) in Figure 1B, and
appropriate enrichment of these genes in the subtypes is clearly
demonstrated. The clustering also distinguished the luminal
subtype. Thus the genes that distinguish ER status in our 5
discovery datasets clearly operate in 3 independent datasets to
achieve not only the separation of tumors by ER status but also by
molecular subtype.
ER2 tumors show higher expression of proliferation
genes than ER+ tumors of the same grade
The ERA genes were analyzed using the ‘‘DAVID’’ tools which
test for over-representation of gene ontologies, pathways and
protein domains. All 12 categories significantly over-represented in
the ERA genes were related to the cell cycle and mitosis (Table 1).
These cell-cycle related ERA genes showed predominantly higher
expression in ER2 tumors, showing that ER2 tumors have a
higher proliferation rate than ER+ tumors even when the tumors
are of the same high grade (Table S2). This is illustrated by an
overlay of the meta-analysis results on pathway maps of key cell
cycle control genes, namely the ‘‘G1 to S Cell cycle control’’
(Figure 2) and ‘‘KEGG Cell Cycle’’ (Figure S2) maps in the
GenMAPP database.
Within the ERA genes, cyclins A1, A2, B2, E1 and J, cyclin
dependent kinase inhibitor 2A (CDKN2A) and CDK2 associated
protein (CDK2AP1) show higher expression in ER2 tumors
whereas cyclins D1, G2 and H, CDK7 and cyclin G-associated
kinase (GAK) have higher expression in ER+ tumors. Several genes
directly involved in DNA replication are more highly expressed in
ER2 tumors: for example, those encoding proteins in the origin-
recognition complex (ORC1L and ORC6L), the minichromosome
maintenance proteins MCM2 to MCM7, and CDC45L.W e
clustered the genes in the cell cycle categories in the validation
datasets, with the samples in forced order first by ER status and
then by ERBB2 levels (Figure S3). The differential expression of
proliferation associated genes was most pronounced in the basal
subgroup of tumors, even when the tumors were of the same grade
(Figure S3A), demonstrating the highly-proliferative nature of
these tumors compared to other molecular sub types.
Investigation of the meta-analysis results using GSEA
GSEA is a method that allows us to search the ERA gene set for
transcript profiles indicative of underlying biological processes. An
initial GSEA study was conducted testing the MolSigDB gene sets
pertaining to chromosomal position, curated gene sets from
publications, and conserved regulatory motifs [26] for enrichment
in the ERA gene set. The complete list of significant associations is
viewable by clicking the index.html file in Dataset S1 to launch
your browser. Inspection of the results revealed the very
prominent enrichment in ER2 tumors of many gene sets relating
to MYC and E2F activity. Although other themes emerge from
this analysis we have concentrated our efforts on these findings.
MYC, like cyclin D1, is a target of E2 and can rescue cell
proliferation in anti-estrogen arrested MCF-7 cells [27]. We
conducted a second GSEA screen after adding extra published
and in-house gene sets (see Materials and Methods) relating to E2-,
MYC- and E2F-activity in cell-lines, with the added datasets
indicated by a prefix of ‘‘MCA’’ (Text S2).
Gene sets associated with ER+ status [4,28] and good outcome
in breast cancer [28] were depleted in ER2 tumors (Text S2.A),
and genes associated with ER2 status [28] and poor outcome [28]
were enriched in ER2 tumors, showing that the meta-analysis
results concur with those of single cohorts. Several gene sets
associated with the cell cycle were enriched in ER2 tumors,
supporting the results from the functional annotation using
DAVID (Text S2.B). The gene sets enriched or depleted with
false discovery rate (FDR),0.05 were examined more closely and
assigned to biological themes; many sets were associated with
chromosomal position, E2-action, MYC action and E2F-action.
We report on these categories in detail in subsequent sections.
Specific cytobands with expression differences between
ER+ and ER2 tumors
DNA copy number alteration shows regional differences
between subtypes of ER+ and ER2 tumors [29,30]. Using GSEA,
we identified cytoband loci containing sets of genes with
expression differences between ER+ and ER2 tumors (Table 2);
genes in these cytobands are marked in the tables of ERA genes in
Table S1. Enriched in ER2 tumors were genes within 6p21,
MYC and E2F
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PLoS ONE | www.plosone.org 4 March 2009 | Volume 4 | Issue 3 | e4710Figure 2. Meta-analysis results for genes in the GenMapp representation of ‘‘G1 to S-phase Cell Cycle Control’’. Genes are colored by
whether they have higher expression in ER+ or ER tumors from the meta-analysis, with the foldchange and significance of this over-expression
represented by the transformed Weighted Average Ratio (tWAR) and BY-adjusted P-value (adj P) respectively.
doi:10.1371/journal.pone.0004710.g002
Table 1. Functional annotation categories from DAVID [6] significantly over-represented in ERA genes.
Category Term Count Un-adjusted P Adjusted P
SP_PIR_KEYWORDS cell cycle 83 2.40E-12 8.87E-08
GOTERM_BP_ALL cell cycle 142 1.35E-11 2.49E-07
KEGG_PATHWAY HSA04110:CELL CYCLE 41 4.55E-10 5.60E-06
GOTERM_BP_ALL regulation of progression through cell cycle 94 1.10E-07 0.00092
GOTERM_BP_ALL regulation of cell cycle 94 1.25E-07 0.00092
GOTERM_BP_ALL mitotic cell cycle 50 7.34E-07 0.0045
GOTERM_BP_ALL cell division 39 1.02E-05 0.038
GOTERM_BP_ALL M phase 43 1.56E-05 0.047
GOTERM_BP_ALL mitosis 36 1.66E-05 0.047
SP_PIR_KEYWORDS cell division 35 1.92E-05 0.047
UP_SEQ_FEATURE domain:Kinesin-motor 13 2.27E-05 0.049
GOTERM_BP_ALL M phase of mitotic cell cycle 36 2.37E-05 0.049
Many categories associated with cell cycle and cell division were significantly over-represented with BY adjusted P,0.05 in the comprehensive ERA gene list.
doi:10.1371/journal.pone.0004710.t001
Figure 1. Hierarchical clustering of ERA genes in cancer samples from A.[13],B . [14], and C.[15]. Each row represents a gene; each column
represents a sample. The expression level of each gene within a sample, relative to that gene’s mean expression across all the samples, is indicated
using a red-blue color scale with red indicating high expression. The dendrogram at the top indicates the similarities between the sample expression
profiles while the side-dendrogram indicates the similarities between gene expression patterns. Figure 1A data is derived from the Richardson
dataset [13] and the top color bars indicate the following: ‘‘ER_Protein’’ – ER status determined using IHC; ‘‘PGR_Protein’’ - PGR status determined
using IHC; ‘‘ERBB2_Protein’’ - ERBB2 status determined using IHC; ‘‘Subtype’’ – Subtype determined from IHC results (Basal, BRCA1 mutation positive,
or non-basal-like carcinoma (‘‘Non-BLC’’)) (see sample key). Figure 1B data is derived from the Wang dataset [14] and the top color bars represent the
following: ‘‘ER_Protein’’ – ER status as determined using ligand binding assay or IHC; ‘‘PGR_Transcript’’, ‘‘ERBB2_Transcript’’ and ‘‘KRT5_Transcript’’:
relative expression measured from quantiles of probe set intensities as described in ‘‘Data Collection’’ in Materials and Methods (see sample key).
Figure 1C data is derived from the Pawitan dataset [15] and the top color bars represent the following: ‘‘Molecular_Subtype’’ – determined by
correlation to the normal-like, Luminal A, Luminal B, ERBB2+ and basal molecular subtypes [16]; ‘‘ER_Transcript’’– Relative expression of the HG-
U133A ESR1 transcript 205225_at measured in quantiles; ‘‘PGR_Transcript’’, and ‘‘ERBB2_Transcript’’ as above; and ‘‘Tumor_Grade’’ – Elston Ellis
grading (see sample key).
doi:10.1371/journal.pone.0004710.g001
MYC and E2F
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genome hybridization (CGH) in basal tumors [31] and 1p34
which shows loss of heterozygosity in ER+ tumors [30]. We note
that gain in 21q22 is associated with poor prognosis [31] and that
this cytoband contains the cell cycle associated ERA genes
CHAF1B and S100B that have elevated expression in ER2
tumors. Depleted in ER2 tumors were the cytobands 4p16, 5q11–
13, 5q22, 5q31, 14q22–23 which show more frequent loss in basal
tumors, and 16p11–p13 which shows more frequent gain in
luminal tumors [30]. The cytobands 14q11–12, 16p12–13, 17q21
and 17q24 were also depleted in ER2 tumors and low resolution
CGH mapping suggests that 14q, 16p and 17q have increased loss
in basal-like tumors [29]. Genes within 17q21 were generally
depleted in ER2 tumors, yet amplification of 17q12–21 is
common in ERBB2+ tumors, which are usually ER2, and
amplification of this region predicts a worse prognosis [31]. Our
study delineated novel sites enriched in ER2 tumors at the
cytobands 2p13, 2p16, 2p21, 2p25, 3q25, 3q29, 6q16, 6q21, 9q21,
11q21–22, 12p13 and 22q13 and depleted in ER2 tumors at
3p21, 11q13, and 12q13. These regions may represent previously
Table 2. Chromosomal position gene sets enriched or depleted in ER2 tumors with FDR,0.05.
Gene Set Name FDR
ERA genes relating to cell cycle and/or cell
proliferation* Enriched or depleted in ER2 tumors
CHR1P34 0.0017 NASP, CDC20, KIF2C, CDCA8 Enriched
CHR2P13 0.010 TGFA Enriched
CHR2P16 0.0081 Enriched
CHR2P21 0.0035 MSH2 Enriched
CHR2P23 0.044 PPP1CB Enriched
CHR2P25 0.033 Enriched
CHR3P21 ,0.0001 APPL, CYB561D2, RBM5, TUSC2, TUSC4 Depleted
CHR3Q25 0.022 Enriched
CHR3Q29 0.024 Enriched
CHR4P16 0.048 GAK Depleted
CHR5Q11 0.0047 Depleted
CHR5Q12 0.048 CDK7 Depleted
CHR5Q13 0.00035 CCNH, F2R, RAD17, RASA1 Depleted
CHR5Q22 0.0094 Depleted
CHR5Q31 0.0050 PURA, SKP1A Depleted
CHR6P21 0.036 RNF8, PIM1, TUBB, GMNN Enriched
CHR6Q16 0.018 Enriched
CHR6Q21 0.0028 HDAC2 Enriched
CHR7Q32 0.0081 Enriched
CHR7Q33 0.041 Enriched
CHR9Q21 0.0044 ANXA1 Enriched
CHR10P13 0.0040 Enriched
CHR11Q13 0.0020 CCND1, VEGFB Depleted
CHR11Q21 0.0058 Enriched
CHR11Q22 0.020 Enriched
CHR12P13 0.010 NOL1, CDCA3 Enriched
CHR12Q13 0.00076 KRT18, MCRS1 Depleted
CHR14Q11 0.00054 Depleted
CHR14Q12 0.050 Depleted
CHR14Q22 0.0097 CGRRF1, HSPA2 Depleted
CHR14Q23 0.021 MNAT1 Depleted
CHR16P11 0.022 Depleted
CHR16P12 0.0079 Depleted
CHR16P13 ,0.0001 E4F1, EMP2, GFER, UBE2I Depleted
CHR17Q21 0.0082 HEXIM1 Depleted
CHR17Q24 0.0039 Depleted
CHR21Q22 0.013 CHAF1B, S100B Enriched
CHR22Q13 0.024 MCM5, GTSE1 Enriched
*Genes are in cell cycle categories in Table S2 and/or the GO0008283 cell proliferation ontology.
doi:10.1371/journal.pone.0004710.t002
MYC and E2F
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reactivation events. ERA genes that had differential expression
consistent with enriched/depleted cytobands and are involved in
cell cycle and/or cell proliferation are marked in Table 2.
Dysregulation of these genes may contribute to the differences in
proliferation rates between ER+ and ER2 cancers.
Direct transcriptional targets of ER are significantly
depleted in ER2 tumors, but indirect E2-induced target
genes are enriched in ER2 tumors
We expected that much of the gene expression differences
between ER+ and ER2 tumors might be due to the ability of ER+
tumors to respond to E2. To distinguish the direct and indirect
effects of E2 we added datasets of direct ER targets derived by
chromatin immunoprecipitation based studies, and datasets
containing both direct and indirect targets characterized by early
response to E2 (Text S2.C, with genes within these datasets
marked in Table S1). Direct ER targets were significantly depleted
in ER2 tumors (8 sets FDR,0.0001 to 0.023, 1 set=0.052), with
depletion of both E2-induced and E2-repressed direct targets [23]
(FDR 0.0013 to 0.021). Surprisingly, sets containing indirectly E2-
induced genes were significantly enriched in ER2 tumors (Text
S2.C) including sets from [24](FDR=0.015) and [32]
(FDR=0.0047), while several sets of genes down-regulated in
response to E2 remained significantly depleted in ER2 tumors
(Text S2.C). An explanation of these observations may be that
transcriptional regulators within the E2 pathway may become
activated independently of the ER in ER2 tumors, driving the
transcription of indirect targets of E2.
High expression of MYC-induced genes and concomitant
low expression of MYC-repressed genes in the basal
subgroup
As seen in Table 3 and Text S2.D, several sets of direct targets
of MYC derived from various experimental and tumor systems,
genes containing MYC binding motifs and MYC-induced genes,
were enriched in ER2 tumors. Prominent among these were sets
of genes induced by MYC in human primary mammary epithelial
cell cultures (HMECs) [22] and in MCF-7 breast cancer cells
[24](both with FDR,0.0001). Notably, the subset of MYC-
induced genes in MCF-7 cells that was also induced by E2 [24] was
highly enriched in ER2 tumors (FDR,0.0001) and the
enrichment plot for this gene set is shown in Text S2.D.i. The
enrichment of the MYC-induced genes in MCF-7 cells taken as a
whole (FDR,0.0001) was greater than the enrichment of E2-
induced genes from the same study (FDR=0.015). MYC-
repressed genes in MCF-7 cells taken as a whole were depleted
in ER2 tumors (FDR,0.0001) (Table 4).
In the ERA genes, 84% of those that were MYC-induced in
MCF-7 cells had significantly higher expression in ER2 tumors,
Table 3. Details of MYC- and E2F-related sets enriched in ER2 tumors with FDR,0.0001.
Gene Set Name Reference Experimental System Description
MCA.Baliciunate_p130.G1_B [37] MEFs (G1 phase), ChIP P130_B
MCA.Musgrove_E2_U and Myc_U [24] Anti-estrogen arrested MCF-7. E2_U and MYC_U
6 hours after E2-induction, or
6 hours after MYC- induction.
MCA.Baliciunate_E2F4.G0_B [37] MEFs (G0 phase), ChIP E2F4_B
MCA.Musgrove_Myc_U [24] Anti-estrogen arrested MCF-7. MYC_U
6 hours after MYC- induction.
MCA.Baliciunate_p107.G1_B [37] MEFs (G1 phase), ChIP P107_B
MCA.BLACK.2005.TOP.100.E2F1-INDUCED
GENES.SUPPLTABLE2
[36] MEFs E2F1_U
VERNELL_PRB_CLSTR1 [35] U2OS E2F_U (Up-regulated by E2Fs 1,2 or 3 and
down-regulated by pRB and p16)
MCA.Baliciunate_p130.G0_B [37] MEFs (G0 phase), ChIP P130_B
MCA.Baliciunate_E2F4.G1_B [37] MEFs (G1 phase), ChIP E2F4_B
YU_CMYC_UP [54] Non-transgenic murine model for B-cell
lymphoma.
MYC_U
MCA.Bild_Myc.LIMMA_U [22] HMEC MYC_U
SGCGSSAAA_V$E2F1DP2_01 [26] NA E2F1_M and TFDP2_M
REN_E2F1_TARGETS [38] WI-38 Primary human fibroblasts, ChIP E2F1_B and E2F4_B
MCA.Zeller_Myc_U and Myc_B [33] Human B lymphoid tumor, ChIP coupled with
pair-end ditag sequencing analysis (ChIP-PET)
MYC_U and MYC_B
MCA.BLACK.2005.TOP.100.E2F3-INDUCED
GENES.SUPPLTABLE3
[36] MEFs E2F3_U
V$E2F1_Q6 [26] NA E2F1 _M
V$E2F4DP2_01 [26] NA E2F4_M +TFDP2_M
V$E2F1_Q6_01 [26] NA E2F1 _M
Tables are sorted by increasing FDR. The suffixes ‘‘U’’, ‘‘D’’, ‘‘B’’ and ‘‘M’’ refer to whether the genes in the set are Up-regulated or Down-regulated by the molecule in
question, Binding Partners (or direct targets) of the molecule identified via chromatin immunoprecipitation (ChIP), or contain Binding Motifs for the molecule in their
promoter regions.
doi:10.1371/journal.pone.0004710.t003
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tumors (Table S1). We therefore examined, in the three validation
datasets, the expression of the ERA genes that were regulated by
MYC in MCF7 cells (Figure 3). With the samples forced to order
first by ER status and then by ERBB2 level we examined the
differential patterns of expression of the Musgrove_Myc_U+D
subset of the ERA genes relative to molecular subtype and the
ability of this gene set to distinguish directly- and indirectly-
regulated E2 and MYC targets. In the left hand side color bars of
the heatmaps we have marked the direction of MYC regulation in
MCF7 cells (Musgrove_Myc_U+D) [24] as well as the direct
targets of MYC defined in B cell lymphoma (Zeller_Myc_B) [33].
Consistent with the results of the meta-analysis and GSEA, the
MYC-induced genes were generally higher in ER2 tumors and
the MYC repressed genes were lower in ER2 tumors in all three
cohorts. The MYC direct targets followed the same trends as the
MYC-regulated genes as a whole.
Since MYC is a direct target of E2, we determined which of
these genes are direct targets of ER (Carroll_ER_B) [23], and how
they are regulated by E2 in MCF7 cells (Musgrove_E2_U+D) [24].
As shown by the left hand side color bars, and consistent with the
GSEA results, the direct targets of ER had higher expression in
ER+ tumors in the three validation datasets. Also as expected,
many of the MYC-regulated genes overlapped with E2-regulated
genes from the same experiment. The overlapping ERA E2-
induced and MYC-induced genes had higher expression in ER2
tumors, and the overlapping ERA E2-repressed and MYC-
repressed genes had lower expression in ER2 tumors.
Importantly, the higher expression of MYC-induced ERA genes
was more pronounced in the basal subgroup than in ER2 tumors
with high ERBB2 expression (P,0.0001 for all three datasets),
(Figure 3). Similarly, the lower expression of MYC-repressed ERA
genes was generally more pronounced in the basal subgroup than
in the ER2/ERBB2+ samples (P,0.0001 for all three datasets),
(Figure 3). When ERA genes regulated by MYC in ER2 HMECs
[22] were used to cluster the validation datasets (Figure S4), we
observed very similar results with respect to the basal subtype,
demonstrating that the MYC pathway is more active in the basal
subgroup and that it mimics estrogen action.
Genes with E2F binding motifs and direct targets of the
E2F family are enriched in ER2 tumors
The E2F family and the proteins that modulate E2F activity are
important for cell cycle progression (reviewed in [34]) In the meta-
analysis, all probe sets for E2F3 and E2F8 showed significantly
higher intensity in ER2 tumors (adjusted P,0.0001 and adjusted
P=0.034 respectively) (Text S3). All probe sets for E2F1 and E2F5
and one probe set for E2F4 had higher intensity in ER2 tumors
(un-adjusted P,0.05), but did not pass the adjusted P significance
threshold. Probe sets for TFDP1 and TFDP2, members of the DP
transcription factor family, whose products form heterodimers
with E2Fs 1 to 6 producing transcription factor complexes that
bind to DNA [34], were significantly higher in ER2 tumors
(TFDP1, adjusted P=0.0073; TFDP2, adjusted P=0.0023). One
probe set for p130, a pocket protein that binds principally to E2Fs
4 and 5 converting them into repressor complexes, had
significantly lower intensity in ER2 tumors (adjusted P=0.0053)
with the other probe set showing the same trend. For each gene
above, the tWAR, indicating fold-change, was small, with the
possible exception of the two probe sets for E2F3 (tWAR=1.48-
fold and 1.88-fold).
In the GSEA screen, several gene sets significantly enriched in
ER2 tumors were associated with E2F activity (Table 3 and Text
S2.E). Nineteen sets contained genes with conserved DNA binding
motifs for E2F family members, particularly E2F1 and E2F4 [26].
Different members of the E2F family can bind to the same genes
depending on the conditions such as the phase of the cell cycle,
and these motif sets had many genes in common. Supporting the
observations for genes with conserved E2F motifs, a MolSigDB list
of genes up-regulated by E2Fs 1, 2 or 3 and down-regulated by
pRB and p16INK4A in U2OS cells [35] was enriched in ER2
tumors (FDR,0.0001) (Table 3). The complementary set of genes
down-regulated by E2Fs 1, 2 or 3 and up-regulated by pRB and
p16INK4A [35] was depleted (FDR=0.038).
In order to better understand the roles E2Fs might play in the
regulation of proliferation in ER2 tumors, we included additional
published sets of direct targets of E2Fs 1, 4 and 6, as well as sets of
genes regulated by E2F1 or E2F3 (Text S2.E). A list of genes
regulated by E2F1 in mouse embryonic fibroblasts (MEFs) was
enriched with FDR,0.0001 (Table 3), as was a set of genes
regulated by E2F3 from the same study [36]. Several sets of direct
targets of E2F1 and E2F4 were significantly enriched in ER2
tumors (Table 3 and Text S2.E). The sets enriched with
FDR,0.0001 included direct targets of E2F4 in MEFs during
either G0 [37] or early G1 stage of the cell cycle [37], genes bound
by both E2F4 and E2F1 in WI-38 primary human fibroblast cells
[38], and genes bound by E2F4 and not E2F1 in the same study
[38]. The pocket proteins p130 and p107 bind to E2F4 converting
it to a repressor complex, and consistent with this association,
direct targets of p130 in MEFs during G0 or G1 [37] were
enriched with FDR,0.0001, as were targets of p107 during G1
[37].
To examine if the enrichment of E2F activity differed between
the subtypes of ER2 tumors, we clustered the validation tumor
datasets using ERA genes that were associated with E2F activity
(Figure S5). We confirmed that the enriched set of direct targets of
E2F4 in MEFs had higher expression in samples with low levels of
ER. These genes had particularly high expression in the basal
subgroup compared to the ER2/ERBB2+ subgroup in all three
datasets (all with P,0.0001), (Figure S5). The ERA genes
Table 4. Details of MYC-related sets depleted in ER2 tumors with FDR,0.0001.
Gene Set Name Reference Experimental System Description
MCA.Musgrove_ Myc_D [24] Anti-estrogen arrested MCF-7. MYC_D
6 hours after MYC-induction.
MCA.Musgrove_E2_D and Myc_D [24] Anti-estrogen arrested MCF-7. E2_D and MYC_D
6 hours after E2-induction, or
6 hours after MYC-induction.
Tables are sorted by increasing FDR. The suffix ‘‘D’’ refers to whether the genes in the set are Down-regulated by the molecule in question.
doi:10.1371/journal.pone.0004710.t004
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cells [35], by E2F1 or E2F3 in MEFs [36] and all the enriched
gene sets of direct targets of E2Fs 1, 4 or 6 also showed differential
expression in the basal tumors (data not shown). ERA genes that
were direct targets of E2F4 and over-expressed in basal ER2
tumors were also over-expressed with respect to normal tissue
(P,0.0001), (Figure S5A).
To ascertain if the enrichment noted for the MYC and E2F sets
was entirely due to the presence of proliferation-associated genes
in these sets, we removed genes in the GO ‘‘cell cycle’’
(GO:0007049) and ‘‘cell proliferation’’ (GO:0008283) categories
from the relevant sets enriched with FDR,0.0001. GSEA showed
that these ‘‘proliferation depleted’’ sets remained as highly
enriched as their complete counterparts, and the leading edges
of the ‘‘proliferation depleted’’ MYC and E2F sets shared few
common genes (data not shown). These results indicate that
outside the shared proliferation-associated genes, MYC-action and
E2F-action are separate forces contributing independently to the
transcriptional differences between ER2 and ER+ tumors.
We also found that the cytobands that were differentially
expressed between ER+ and ER2 tumors did not contain MYC
or genes known to influence MYC-activity (such as the binding
partners MAD or MAX). Similarly, the enriched or depleted
cytobands did not contain any members of the E2F family that
were differentially expressed in the meta-analysis, or any genes
known to influence E2F-activity (such as members of the families
of DP transcription factors or pocket proteins). It is therefore
unlikely that genetic alterations in these regions are the cause of
the increased MYC and E2F activity in ER2 tumors.
Discussion
This study uses a novel meta-analysis approach to identify genes
and genetic pathways associated with ER status in breast cancer.
Importantly, we restricted our analysis to grade 3 tumors because
ER2 tumors are almost exclusively of higher grade while ER+
tumors show greater diversity. Thus previously published lists of
ER status-associated genes [3–5] may contain genes related to
grade in addition to ER status. Functional annotation analysis of
the 2141 ERA genes using DAVID and GSEA showed that
categories associated with cell cycle were enriched in genes up-
regulated in ER2 tumors compared to ER+ tumors indicating
that even at the same grade, ER2 tumors exhibit a greater
proliferation signal. Hierarchical clustering of the validation
datasets revealed that cell-cycle associated genes are more highly
expressed in the basal subgroup than in other ER2 tumors. While
other transcript profiling studies have reported that cell cycle and
cell proliferation categories are over-represented in molecular
basal tumors [39], they were unable to uncouple the effects of
grade and ER status as we have done, due to restricted numbers of
samples in their studies. Our results concur with those of a recent
histopathological study confined to Grade 3 invasive ductal
carcinomas, which found that the basal phenotype was highly
significantly associated with high total mitotic count, a marker of
increased proliferation [40].
In the GSEA screen, independent lists of direct targets of the
E2/ER complex were depleted in ER2 tumors as one would
expect. The genes induced by E2 in MCF-7 cells in two studies
were enriched in ER2 tumors, and E2-repressed genes from four
studies were depleted in ER2 tumors. Consistent with our results,
previous studies aiming to identify E2-induced genes over-
expressed in ER+ tumors found fewer genes than expected
[4,41], and small subsets of E2-induced genes were observed to be
over-expressed in ER2 tumors [41,42]. These apparent discrep-
ancies were attributed to differences between tumors and cell lines
[4,41]. Our results provide an alternative explanation: aberrant
activation of the E2-target MYC leads to a robust induction of a
subset of genes characteristic of an E2 response. Consistent with
this hypothesis, MYC is capable of rescuing cell cycle progression
in MCF-7 cells arrested in G1 phase by pre-treatment with an
estrogen antagonist [27] and a large proportion of the ERA genes
regulated by E2 in MCF-7 cells are also MYC-regulated (Figure 3,
Figure S4 and associated references). Unlike the direct targets of
E2, both the direct targets of MYC in B-cell lymphoma and genes
containing MYC binding motifs were enriched in ER2 tumors.
Our results support and extend those of Creighton et al. [32] who
reported that a single list of genes which showed early and
sustained induction by E2 in ER+ cell lines (labeled as
‘‘MCA.Creighton.Cluster B Genes_E2_Early.Sustained_U’’ in
our GSEA screen) was enriched in ER2 tumors in a cohort of
Grade 1 to 3 tumors.
A wide range of MYC transcript levels by RT-PCR has been
detected in both ER+ and ER2 breast cancers [43]. In our meta-
analysis, the expression of MYC was significantly higher in ER2
tumors (adjusted P=0.024), corroborating the results of a single
cohort study [44]. MYC copy number amplification is associated
with loss of ER and PGR in one cohort [45] and is not associated
with ER positive status in another cohort [46]. Amplification of
the MYC gene and/or over-expression of MYC protein is
associated with high grade in some cohorts [44,47]. Rhodes et al.
[48] reported the presence of a set of genes activated by MYC in
HMECs [22] in signatures of Grade 3 breast cancer.
We observed higher levels of MYC transcripts in the basal
subtype compared to ER2/ERBB2+ samples in two of our
validation cohorts. MYC is significantly amplified in tumors with
BRCA1 mutations which have a profile similar to basal tumors [49]
but amplification of MYC is not correlated with the basal
phenotype [46], suggesting that the high transcript levels of
MYC we observed in ER2 tumors may be due to factors other
than MYC amplification. By classifying samples in the validation
cohorts into the predicted subtypes of breast cancer, we made the
novel observation that the elevated expression of MYC-induced
genes, including MYC direct targets, and the lower expression of
MYC-repressed genes distinguishes the basal subgroup of ER2
tumors. Furthermore, in a concurrent study from this laboratory,
we have also observed that expression of c-Myc with a
Figure 3. Hierarchical clustering of 500 MYC-responsive ERA genes [24] in validation datasets from A.[13],B . [14], and C.[15]. The first
top color bar of Figure 3A. represents whether the sample is a breast cancer or from normal breast tissue. The remaining top color bars of Figure 3A
are equivalent to those in Figure 1A. The colors in the side color bars represent the following: yellow=an E2-induced gene, purple=an E2-repressed
gene, orange=a MYC-induced gene, blue=a MYC-repressed gene and red indicates a gene which is a direct target of ER (‘‘ER_B’’ suffix), or a direct
target of MYC (‘‘Myc_B’’). Moving from right to left, for each gene, the first side color bar represents the transcriptional response to MYC in MCF-7 cells
[24] (Musgrove_Myc_U+D). The next color bar represents whether the gene was classified as being a direct target of MYC in B cell lymphomas [33]
(Zeller_Myc_B). The next two color bars represent how this gene was regulated by E2 in MCF-7 cells [24] (Musgrove_E2_U+D), and whether it
contained an ER-binding site with 50 kbp of the promoter region [23] (Carroll_ER_50 kbp_B). The top color bars of Figure 3B are equivalent to those
of Figure 3B, and the side color bars are the counterparts of those in Figure 3A. The top color bars of Figure 3C. are equivalent to those of Figure 3C,
and the side color bars are the counterparts of those in Figure 3A.
doi:10.1371/journal.pone.0004710.g003
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correlates with the basal phenotype as determined by an ER2/
PGR2/ERBB22/KRT5/6+ staining pattern (McNeil CM,
Musgrove EA and Sutherland RL, manuscript in preparation).
The MYC transcript was over-expressed in the basal subtype
compared to ER2/ERBB2+ samples in two of our validation
cohorts, Richardson P=0.036, Pawitan P=0.00013, but not in
Wang P=0.964. MYC over-expression in basal cancer in other
datasets can be distinguished on the basis of frequency [50], but
our analysis of the five meta-analysis datasets indicates that it is not
a prominent feature, ranking below the top 1000 differentially
expressed mRNAs. Thus the strong transcriptional effect of MYC
that we have detected suggests that more than altered MYC
expression is contributing to its activity in basal breast cancer.
Our study also highlights the role of the E2F family in ER2
tumors, and shows that their dysregulation may play a role in the
proliferation of basal tumors. E2Fs are known to control the
expression of genes important for cell cycle progression as well as
genes involved in apoptosis and differentiation [34]. E2F binding
motif gene sets were enriched, as were several lists of direct targets
for E2F1, 4 and/or 6. As E2F family members overlap
considerably in their binding specificity, we conclude that the
direct binding of one or more members of the E2F family is
increased in ER2 tumors, but cannot specify which family
member. The actions of the E2F family members are closely linked
with those of MYC. The MYC protein can regulate the E2Fs [51],
and vice versa [52]. Many of the genes regulated by various E2Fs
during the early events of the cell cycle are also regulated by MYC
[33,52]. The MYC gene is bound by E2F4 but not p130 or p107
during G0 (but not G1) in MEFs [37]. MYC is a direct target of
E2F1 in human fibroblasts [38]. E2F3, E2F5 and TFDP1, which
have higher expression in ER2 tumors, are all induced by MYC
in MCF-7 cells [24]. Zeller et al. [33] found the E2F1 binding motif
is enriched 16-fold in clusters of MYC-binding genes, and 37-fold
within the subset of E-box containing genes. In our study, the
genes shared between gene sets relating to MYC- and E2F-action
were predominantly proliferation-associated genes. In this context,
we believe that dysregulation or constitutive activation of processes
regulated by MYC in conjunction with increased E2F activity may
lead to uncontrolled cell cycle progression and proliferation, such
as we see in ER2 tumors and particularly in the basal subtype
within the ER2 tumors. Kreike et al. [53] showed that the basal
subtype may be further divided into five subgroups on the basis of
gene expression profiles. A group of proliferation-associated genes
was among those contributing to the clustering. The enrichment of
MYC- and E2F-regulated genes in the genes partitioning the basal
tumors in the cohort of Kreike et al. [53] may prove a valuable
avenue of investigation. Our findings may also have important
therapeutic implications. A recent bioinformatic study indicated a
significant association between the set of genes activated by MYC
in HMECs [22], and genes repressed on treatment of MCF-7 or
HL-60 cells with the PI3K signaling pathway inhibitors wortman-
nin or LY-294002 [48]. MYC-activated genes had lower
expression in cells treated with wortmannin or LY-294002,
suggesting that PI3K inhibitors repress MYC-activation [48].
Our study provides strong evidence for MYC-action in basal
tumors, suggesting that PI3K inhibitors, and other potential
repressors of MYC-action, should be investigated as therapeutic
candidates for these tumors which have no targeted therapies at
present. We anticipate that the biological insights generated by this
study will prove valuable in the development of new therapeutic
strategies for the poor prognosis ER2 tumors and in particular the
basal subtype. We conclude that over-expression or constitutive
activation of MYC, possibly in conjunction with elevated E2F
activity, may contribute to increased proliferation in ER2 breast
tumors, particularly in the basal subgroup.
Supporting Information
Dataset S1 GSEA results from first screen. The file contains a
zipped archive of the HTML results of the second GSEA screen.
Reports for enriched or depleted datasets may be accessed from
the ‘‘index.html’’ link within the my_analysis.GseaPreran-
ked.1219975950625.rpt.zip ZIP archive. Enrichment plots are
available for each of the 50 most enriched and depleted gene sets.
Found at: doi:10.1371/journal.pone.0004710.s001 (13.32 MB
ZIP)
Figure S1 Principal components analyses (PCAs) using ERA
genes on Grade 3 and Grade 2 ER+ and ER2 samples. The ERA
genes were identified by a meta-analysis of Grade 3 samples in five
datasets (Farmer, Sotiriou.JRH.Untreated, Miller, Minn and
Sotiriou.Uppsala). To demonstrate that these ERA genes also
separate Grade 2 ER+ and ER2 tumors, PCAs using the ERA
genes were performed on Grade 2 samples from those same five
datasets. The PCAs of Grade 3 samples in the Farmer,
Sotiriou.JRH.Untreated, Miller, Minn and Sotiriou.Uppsala
datasets are found in Figure S1A.i–v; PCAs of Grade 2 samples
in the Farmer, Sotiriou.JRH.Untreated, Miller, Minn and
Sotiriou.Uppsala datasets are found in Figure S1B.i–v.
Found at: doi:10.1371/journal.pone.0004710.s002 (0.54 MB TIF)
Figure S2 Meta-analysis results for genes in the GenMapp
representation of KEGG Cell Cycle. Genes are colored by
whether they have higher expression in ER+ or ER tumors from
the meta-analysis, with the foldchange and significance of this
over-expression represented by the transformed Weighted Average
Ratio (tWAR) and BY-adjusted P-value (adj P) respectively.
Found at: doi:10.1371/journal.pone.0004710.s003 (0.08 MB TIF)
Figure S3 Hierarchical clustering of expression data from cell-
cycle-associated genes in datasets from A. Richardson et al. (2006),
B. Wang et al. (2005), and C. Pawitan et al. (2005). The two-way
clustering of the ERA genes and samples previously (Figure 1) had
indicated that the ERA genes were differentially expressed
between the ER+, basal and ER2/ERBB2+ tumor subtypes. In
order to clarify the behavior of the cell-cycle-associated genes in
the different subtypes, we ordered the samples in the validation
datasets primarily by ER status and secondarily by ERBB2 status,
and then clustered only the cell-cycle-associated genes while
maintaining the order of the samples. Figure S3A data is derived
from the Richardson dataset (Richardson et al., 2006) and the top
color bars indicate the following: ‘‘Sample Type’’ - whether the
sample is a breast cancer or from normal breast tissue;
‘‘ER_Protein’’ - ER status determined using IHC; ‘‘PGR_Protein’’
- PGR status determined using IHC; ‘‘ERBB2_Protein’’ - ERBB2
status determined using IHC; ‘‘Subtype’’ - Subtype determined
from IHC results (Basal, BRCA1 mutation positive, non-basal-like
carcinoma (‘‘Non-BLC’’), or Normal tissue) (see sample key).
Figure S3B. data is derived from the Wang dataset (Wang et al.
2005) and the top color bars represent the following: ‘‘ER_Pro-
tein’’ - ER status as determined using ligand binding assay or IHC;
‘‘ER_Transcript’’, ‘‘PGR_Transcript’’, ‘‘ERBB2_Transcript’’ and
‘‘KRT5_Transcript’’: relative expression measured from quantiles
of probe set intensities as described in ‘‘Data Collection’’ in
Materials and Methods (see sample key). Figure S3C. data is
derived from the Pawitan dataset (Pawitan et al. 2005) and the top
color bars represent the following: ‘‘Molecular_Subtype’’ -
determined by correlation to the normal-like, Luminal A, Luminal
B, ERBB2+ and basal molecular subtypes (Sorlie et al. 2001);
MYC and E2F
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as above; and ‘‘Tumor_Grade’’ - Elston Ellis grading (see sample
key). Two major clusters of cell-cycle-associated genes were
observed in all three heatmaps; in each dataset, the highest
expression of cell-cycle genes was observed in the basal samples, as
marked.
Found at: doi:10.1371/journal.pone.0004710.s004 (0.36 MB TIF)
Figure S4 Hierarchical clustering of expression data from 130
MYC-responsive ERA genes (Bild et al., 2006) in datasets from A.
Richardson et al. (2006), B. Wang et al. (2005), and C. Pawitan et
al. (2005). The ERA Bild_MYC_U+D genes are ERA genes that
were also regulated by MYC in HMECs (Bild et al. 2006). We
clustered these genes in the three validation datasets while
maintaining the sample order. In Figure S4A, the top color bars
are equivalent to those of Figure S3A. The colors in the side color
bars represent the following: yellow=an E2-induced gene,
purple=an E2-repressed gene, orange=a MYC-induced gene,
blue=a MYC-repressed gene and red indicates a gene which is a
direct target of ER (‘‘ER_B’’ suffix), or a direct target of MYC
(‘‘Myc_B’’). Moving from right to left, for each gene, the first two
side color bars represent the transcriptional response to MYC in
HMECs (Bild et al., 2006) (Bild_MYC_U+D), and in MCF-7 cells
(Musgrove et al., 2008; McNeil et al., 2006) (Musgrove_My-
c_U+D). The next color bar represents whether the gene was
classified as being a direct target of MYC in B cell lymphomas
(Zeller et al., 2006) (Zeller_Myc_B). The next three color bars
represent how this gene was regulated by E2 in MCF-7 cells at
6 hours (Musgrove et al., 2008; McNeil et al., 2006) (Musgrove_
E2_U+D), and at 3 hours (Carroll et al., 2006) (Carroll_3 hr_
E2_U+D), and whether it contained an ER-binding site with
50 kbp of the promoter region (Carroll et al., 2006) (Carrol-
l_ER_50 kbp_B). The top color bars of Figure S4B are equivalent
to those of Figure S3B, and the side color bars are the counterparts
of those in Figure S4A. The top color bars of Figure S4C are
equivalent to those of Figure S3C, and the side color bars are the
counterparts of those in Figure S4A. It can be seen that the
majority of ERA MYC-induced genes have higher expression in
the basal tumors, and the majority of ERA MYC-repressed genes
have lower expression in basal tumors.
Found at: doi:10.1371/journal.pone.0004710.s005 (0.48 MB TIF)
Figure S5 Hierarchical clustering of MCA.Baliciunate_
E2F4.G0_B ERA genes (Baliciunate et al., 2005) in datasets from
A. Richardson et al. (2006), B. Wang et al. (2005), and C. Pawitan
et al. (2005). The MCA.Baliciunate_E2F4.G0_B genes are direct
targets of E2F4 in mouse embryonic fibroblasts (Baliciunate et al.,
2005). In Figure S5, the top color bars are equivalent of Figure
S5A, S5B and S5C are equivalent to those of to those of Figure
S3A, S3B and S3C respectively.
Found at: doi:10.1371/journal.pone.0004710.s006 (0.35 MB TIF)
Table S1 The HG-U133A probe sets and their biological
associations. A zipped EXCEL spreadsheet containing all 22,283
HG-U133A probe sets, along with Probe Set ID, Representative
public database IDs (RefSeq transcript, Entrez, and Unigene),
Gene Name, Gene Symbol, Z score, BY-adjusted P-value, status as
an ERA gene, transformed Weighted Average Ratio, as well as
whether they have an association with, E2-action, MYC-action,
E2F-action, the cell cycle or significantly enriched or depleted
chromosomal position in several different datasets. A negative
‘‘Overall Z score’’ indicates a probe set with higher intensity in
ER2 tumors.
Found at: doi:10.1371/journal.pone.0004710.s007 (3.78 MB ZIP)
Table S2 Cell cycle genes over-expressed in ER2 or ER+
tumors. Cell cycle associated genes, and their over-expression in
ER2 tumors or ER+ tumors from the meta-analysis.
Found at: doi:10.1371/journal.pone.0004710.s008 (0.02 MB
PDF)
Text S1 Supplementary Methods
Found at: doi:10.1371/journal.pone.0004710.s009 (0.10 MB
DOC)
Text S2 Behavior of major biological categories enriched or
depleted in ER2 tumors in GSEA. Tables are sorted by increasing
FDR. Gene sets linked with Estrogen (E2), MYC or E2F activity
have been labeled with suffixes ‘‘U’’, ‘‘D’’, ‘‘B’’, ‘‘Dir’’ and ‘‘M’’
referring to whether the genes in the set are Up-regulated or
Down-regulated by the molecule in question, Binding Partners (or
direct targets) of the molecule identified via ChIP, other Direct
targets of the molecule identified by the use of cycloheximide, or
whether they contain conserved Binding Motifs for the molecule in
their promoter regions.
Found at: doi:10.1371/journal.pone.0004710.s010 (0.47 MB
DOC)
Text S3 Behavior of probe sets for MYC, E2F and associated
genes in the meta-analysis.
Found at: doi:10.1371/journal.pone.0004710.s011 (0.09 MB
DOC)
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